Building the medical affairs organisation of tomorrow

Medical affairs has a lot on its plate. As the pharma model has been shifting from primary-care, blockbuster-drug discovery through to more specialised medicine and gene therapy, the science has naturally become more complicated. ‘  The rise of artificial intelligence and big data means evidence generation now goes far beyond interventional studies, while the environment continues to demand more discussion around value and pricing.    Unwrapping complex science and value makes for a challenging remit for medical – without adding the shifting demands caused by the changing working patterns and global uncertainty of the COVID-19 pandemic.   Now, more than ever, is the time to meet stakeholders where they are, which may be somewhere very different to where they were merely months ago.   The diversification of the stakeholder“Medical affairs is a unique department,” says Charlotte Kremer, EVP, Head of Medical Affairs, Astellas. “It ' s not only clinical trials, it ' s not only communication – it’s both. It is really a combination of evidence generation and scientific exchange. I always consider medical affairs the stewards of knowledge.”  If the department ’s main external stakeholders have historically been HCPs and academic thought leaders, it has long since widened out to include communication with payers and HTA bodies.   A further stakeholder, however, is emerging as a key focus for the future. “Lately, with patient-centricity groups either...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news